
Michael Palantoni is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
Michael Palantoni is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
Brenden O'Hara, clinical pharmacist of Blue Cross Blue Shield of North Carolina, discusses innovations in diabetes management and what’s to come in 2022 at AMCP Nexus 2021.
Juday, director of specialty product development at CVS Health, shares how CBT’s for insomnia can save payers and can yield cost savings with or without a digital component.
Consultant Jeffrey Casberg says biosimilars are coming on strong and that interchangeability may not be much for the products dispensed through specialty pharmacies because specialty pharmacies are often in frequent touch with physicians.
Page and Taddei-Allen of WellDyne discuss precision medicine and its implications for pharmacy management at this year's AMCP Nexus Conference
Melissa Andel, principal of CommonHealth Solutions, discusses Medicare Part D in the future — more particularly in the next year — and why these changes are being made during this year's AMCP Nexus conference.
Shantanu Nundy, M.D., MBA, chief medical officer at Accolade, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video he talks about the career achievement that has given him the greatest satisfaction and who has had the greatest influence in his life, which are his parents, sister and aunt and uncle.
Shantanu Nundy is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
A panel discussion on prescription digital therapeutics identified them as a sweet spot for value-based agreements and collection of real-world evidence. But should they be paid for through the pharmacy benefit? And is there enough evidence available for payers and PBMs to make sound coverage and formulary decisions? For answers, stay tuned.
Joan Barrett of Axene Health Partners and Nicole Bulochnik of Optum discuss value-based care models and actuaries' involvement during this year's AMCP Nexus conference.
Christina Barrington, VP of pharmacy programs at Priority Health, spoke at AMCP Nexus 2021 about the value of managed care, real-world evidence and more.
Melissa Hanna, J.D., MBA, co-founder and CEO of Mahmee in Los Angeles, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and who has had the greatest influence on her life, which is her mother.
Melissa Hanna is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
The growing ranks of FDA-approved orphan drugs for rare diseases have saved and improved many lives. But the high-priced drugs are also a major cost burden.
Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months
Barlow spoke at AMCP Nexus about gene and cell therapy and about how payment models need to adjust to account for their high initial cost and their durable — in some cases lifetime — effects.
Loucks, manager of specialty clinical pharmacy programs and formulary at Kaiser Permanente Washington, discusses metrics that might give healthcare providers an incentive to address healthcare disparities and concrete steps that could be taken to turn the talk about addressing healthcare disparities into a reality.
If the new drug is approved, a Mayo Clinic expert on hypertrophic cardiomyopathy sees the new medication as probably being among the second-line choices for patients who don’t respond to beta blockers and calcium channel blockers.
Rachel Goldberg, B.S.N, RN, director of behavioral health client partnerships and product innovation at Horizon Blue Cross Blue Shield of New Jersey, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and who has had the greatest influence on her life.
Rachel Kotok Goldberg is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
The first panel discussion of the meeting was a window into the variety of ways that health plans are working to close health disparities.
Ann Mary Ferrie of Visiting Nurse Service of New York is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and who has had the greatest influence on her life, which is her mother.
Ann Mary Ferrie is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
In COVID-19 news: An advisory committee recommends both J&J's and Moderna’s booster, Regeneron seeks full approved for its treatment and Merck seeks EUA for treatment. In cancer, the FDA approves Verzenio for early breast cancer, Keytruda for advanced cervical cancer, and Tecentriq in early nonsmall cell lung cancer.
The committee’s two-day meeting resulted in recommended approvals for both J&J’s and Moderna’s COVID-19 booster.
Harold Carter of Express Scripts is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video he talks about the career achievement that has given him the greatest satisfaction and who has had the greatest influence on his life, which is his grandfather he is named after.
Harold Carter is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.
Health plans need to consider regulations and keep healthcare data secure to take full advantage of its enormous potential to broaden and reshape timely, effective delivery of care.
This European study enrolled patients with more severe cases of spinal muscular atrophy than a similar study conducted in the U.S.